Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide + Vitamin C + Melphalan in Multiple Myeloma
NCT00661544Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2004
- Primary completion
- Jun 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of arsenic trioxide in multiple myeloma (MM) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response Rate at 12 months. Started Mar 2004; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00661544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661544.